MTOR and systemic lupus erythematosus: Although comprehensive skin-based metabolic studies are limited, insights from SLE models indicate that aberrant glycolytic activity, increased ROS production, and activation of mammalian Target of Rapamycin (mTOR) pathway may similarly affect immune and stromal cells within CLE lesions [38,39,40].